Pyridoxine

Pyridoxine

SCHEMBL3497798

Cc1ncc(CO)c(CO)c1O.[NaH]

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.96
KDM4E B2RXH2 2/20 0.96
ALDH1A1 P00352 2/20 0.96
HSD17B10 Q99714 1/20 0.96
LMNA P02545 3/20 0.73
PDXK O00764 3/20 0.58
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
AOX1 Q06278 1/20 0.56
TRIM24 O15164 1/20 0.54
TRIM33 Q9UPN9 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C19 P33261 1/20 0.54
HIF1A Q16665 1/20 0.54
GAA P10253 1/20 0.49
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
CA9 Q16790 3/20 0.45
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridoxine SCHEMBL30877002 0.98 HPGD (1.00) HPGDKDM4EALDH1A1HSD17B10LMNA
Pyridoxine SCHEMBL30267871 0.98 HPGD (1.00) HPGDKDM4EALDH1A1HSD17B10LMNA
Pyridoxine SCHEMBL3506 0.98 HPGD (1.00) HPGDKDM4EALDH1A1HSD17B10LMNA
Pyridoxine SCHEMBL2322958 0.98 HPGD (1.00) HPGDKDM4EALDH1A1HSD17B10LMNA
Pyridoxine SCHEMBL8733421 0.96 HPGD (0.96) HPGDKDM4EALDH1A1HSD17B10LMNA
Pyridoxine SCHEMBL4900587 0.96 HPGD (0.96) HPGDKDM4EALDH1A1HSD17B10LMNA
Pyridoxine SCHEMBL42293 0.96 KDM4E (0.96) HPGDKDM4EALDH1A1HSD17B10LMNA
Pyridoxine SCHEMBL5370659 0.96 HPGD (0.96) HPGDKDM4EALDH1A1HSD17B10LMNA
Pyridoxine SCHEMBL5611277 0.96 HPGD (0.96) HPGDKDM4EALDH1A1HSD17B10LMNA
Pyridoxine SCHEMBL7588196 0.96 KDM4E (0.96) HPGDKDM4EALDH1A1HSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117064898-A Application of pirenoxine sodium in preparing antitumor drug 江西中医药大学 2023-11-17 CN disclosed
CN-107920973-B Surface modification composition 株式会社LG生活健康 2021-05-07 CN disclosed
US-20100129913-A1 POLIOMA VECTOR EXPRESSING LONG DOUBLE-STRANDED RNAS VAN HOLST GERRIT JAN 2010-05-27 US disclosed
EP-2035557-A2 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Phytovation B.V. (NL) 2009-03-18 EP disclosed
WO-2008000779-A2 POLIOMA VECTOR EXPRESSING LONG DOUBLE-STRANDED RNAS PHYTOVATION BV (NL) 2008-01-03 WO disclosed
US-20050260166-A1 Expressional enhancers from viruses PHYTOVATION B.V. (NL) 2005-11-24 US disclosed
CN-1659281-A Antiviral therapy on the basis of RNA interference VIRUVATION B V (NL) 2005-08-24 CN disclosed
US-20050182010-A1 Use of a nucleotide construct stably integrated in the genome of the target cells of the virus, which is able to produce a single transcript or multiple transcripts capable of forming a double-stranded RNA which inhibits replication of the virus VIRUVATION B.V. (NL) 2005-08-18 US disclosed
EP-1551981-A1 EXPRESSIONAL ENHANCERS FROM VIRUSES Phytovation B.V. (NL) 2005-07-13 EP disclosed
EP-1495122-A1 ANTIVIRAL THERAPY ON THE BASIS OF RNA INTERFERENCE Viruvation B.V. (NL) 2005-01-12 EP disclosed
WO-2004035796-A1 EXPRESSIONAL ENHANCERS FROM VIRUSES PHYTOVATION B.V. (NL) 2004-04-29 WO disclosed
WO-2003087371-A1 ANTIVIRAL THERAPY ON THE BASIS OF RNA INTERFERENCE VIRUVATION B.V. (NL) 2003-10-23 WO disclosed